cisatracurium has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JM; Shan, GF; Wang, L; Xia, YZ; Yang, H; Zha, J; Zhang, XS | 1 |
| Lu, Z; Wen, Q; Yabasin, IB; Yu, JC | 1 |
2 other study(ies) available for cisatracurium and Colorectal Neoplasms
| Article | Year |
|---|---|
Cisatracurium regulates the CXCR4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling.
Topics: Animals; Atracurium; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; HCT116 Cells; Heterografts; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Receptors, CXCR4; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro.
Topics: Apoptosis; Atracurium; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; HCT116 Cells; Humans; Signal Transduction; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2017 |